Addressing the challenge of managing inherent variability when working with AAV vectors to accelerate the development of novel gene therapies
Time: 2:20 pm
day: Day One
Details:
- Examine the causes of analytical bottlenecks in bioprocess development when evaluating AAV vectors, where time is of the essence
- Highlight the importance of monitoring AAV titre to establish robustness and consistency in the process, to identify issues early and support technology transfer to GMP
- Discuss choosing the right AAV quantification method through a comparison of viral particle titres between the established automated ELISA method and the Redox Electrochemical Detection (RED) method of Amperia, against the key priorities of speed, accuracy, flexibility and measuring from crude samples
